PRIMARY STUDY
Dual inhibition of cannabinoid CB 1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease
Key Findings: The hybrid inhibitor ameliorated obesity-induced kidney morphological and functional changes via decreasing kidney inflammation, fibrosis, oxidative stress, and renal injury. Some of these features were independent of the improved metabolic profile mediated via inhibition of CB1 receptors.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Israel, United States
Year of Pub: 2020
Cannabinoids Studied: Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1
Dosage: MRI-1867 (3 mg·kg-1 ), JD5037 (3 mg·kg-1 ), and iNOS antagonist 1400W (10 mg·kg-1 ),
Route of Administration: Injection
Citation: Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease. Br J Pharmacol. 2020; 177:110-127. doi: 10.1111/bph.14849
Authors: Udi S, Hinden L, Ahmad M, Drori A, Iyer MR, Cinar R, Herman-Edelstein M, Tam J
